摘要
正常ＳＤ大鼠皮下注射ｒＨｕＥＰＯ（人基因重组红细胞生成素）的Ｆ参数（相对生物利用度）显著高于腹腔注射．单次皮下注射１００Ｕ／ｋｇ时，正常人、尿毒症未透析和腹透组ｔ１／２β（消除相半衰期）分别为１５．４±０．９、１６．６±６．９和９．２±２．７ｈ．在尿毒症未透析组，皮下注射后血药浓度下降缓慢，Ｆ为（４１±１７）％，用药４８ｈ后仍为基础浓度的３倍左右。表明ｒＨｕＦＰＯ以皮下用药更为合适。
The mean biovailability(F) after s.c. injection of rHuEPO was signincantly higher than that after i.p. injection in healthy SD rats. The mean t1/2β after a s.c.dose of 100U/kg in normal human volunteers, pre-dialysis and peritoneal dialysis uremic patients were 15.4 ± 0.9, 16.6 ± 6.9 and 9.2 ± 2.7 h respectively. In pre-dialysis patients, the mean F after a s.c. dose was 41 ± 17%. Serum rHuEPO concentrations after a s.c. dose decreased slowly and were over three times of baseline 48 hours later. It is concluded that s.c. administration is the optical route for rHuEPO.
出处
《核技术》
CAS
CSCD
北大核心
1994年第11期680-683,共4页
Nuclear Techniques
